ArticleMolecular neurobiology2025
Evaluation of 5-hydroxytryptamine (5-HT) on Cognitive Function in Rats with Gut-Brain Axis Dysfunction Following Acceleration Exposure.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To investigate how 5-hydroxytryptamine (5-HT) modulates acceleration-induced gut-brain axis dysfunction (10 gravitational acceleration [Gz]) and its cognitive impacts in rats, focusing on microbiota-immune interactions and hippocampal neuroinflammation. Sixty male Sprague-Dawley rats were divided into four groups (n = 15/group): Control (0 Gz); + 10 Gz (acceleration exposure via animal centrifuge at 10 Gz for 5 min); 5-HT-Enriched + 10Gz (tryptophan 2.4%) and5-HT-Depleted + 10Gz (tryptophan 0%). Cognitive assessments (Morris water maze, open-field test) and sample collection were performed at 6, 24, and 72 h post-exposure. Serum 5-HT, tumor necrosis factor-alpha (TNF-α), and interleukin-1β (IL-1β) levels were quantified by enzyme-linked immunosorbent assay (ELISA). Hippocampal CA1 microglial activation was assessed by CD11b/Iba-1 immunofluorescence. Fecal microbiota composition was analyzed via 16S ribosomal RNA sequencing (V3-V4 region, QIIME2 pipeline). + 10 Gz group showed prolonged escape latency (72 h: 111.88 ± 7.96 s vs. control 32.15 ± 5.43 s, P < 0.001) and reduced open-field exploration (central crossingsat 6 h: 9.60 ± 2.88 vs. control 21.4 ± 8.26, P < 0.05), which was reversed by 5-HT supplementation (escape latency at 72 h: 34.12 ± 4.21 s, P < 0.001). + 10 Gz increased Firmicutes/Bacteroidetes ratio (62.1%:18.7% vs. control 48.3%:32.5%), while 5-HT-Enriched + 10Gz enhanced Lactobacillus abundance (21.3% vs. + 10Gz 8.7%, P < 0.05). Serum TNF-α (72 h: 5.56 ± 0.40 pg/mg vs. control 0.12 ± 0.03 pg/mg) and IL-1β (4.21 ± 0.32 pg/mg vs. 0.08 ± 0.01 pg/mg) surged following acceleration exposure (P < 0.001). 5-HT supplementation significantly attenuated these cytokine elevations, with TNF-α reduced to 8.34 ± 0.19 pg/mg (P = 0.003) and IL-1β to 4.41 ± 0.47 pg/mg (P = 0.02) compared to the + 10Gz group. Meanwhile, hippocampal CA1 microglial activation progressively increased (CD11b + area: 6 h 28.3 ± 3.1% → 72 h 45.6 ± 4.8%, P < 0.001), which was attenuated by 5-HT (19.7 ± 2.3%, P < 0.01). 5-HT ameliorates acceleration-induced cognitive deficits by rebalancing gut microbiota and suppressing CA1-specific neuroinflammation, suggesting therapeutic potential for gut-brain axis disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.